The abstract is read at the publisher; the summary is JClub's.
In Ethiopia’s IMPROV and OPRA radical cure trials, probabilistic microhaplotype genotyping shows hypnozoite relapse dominates recurrent Plasmodium vivax infections without primaquine, with p(L) ≥ 0.75.
- Why it matters: Relapse origin is needed to quantify the hypnozoite reservoir’s public health burden, transmission potential, and whether anti-relapse therapy works.
- What they did: Parasite isolates from enrolment and recurrences were genotyped using 93 genome-wide markers, then classified with a Bayesian hierarchical model (Pv3Rs) over 12-month follow-up in IMPROV (604 samples/444 participants) and OPRA (621/342).
- The result: Probable relapse was the dominant classification without primaquine (75.5% and 75.2%), and primaquine sharply reduced probable relapse from 57.3% to 1.7% (IMPROV) and 60.2% to 9.5% (OPRA).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.